Earnings release
Page 1
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. RemeGen Co., Ltd.* Ⴁᖹ ( ̨ )ʮ̡ (A joint stock company incorporated in the People ’s Republic of China with limited liability) (Stock Code: 9995) 2025 THIRD QUARTERLY REPORT This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Reference is made to the “RemeGen Co., Ltd. 2025 Third Quarterly Report ” published by RemeGen Co., Ltd.* (the “Company ”) on the website of the Shanghai Stock Exchange, for reference purpose only. The following is a translation of the 2025 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version shall prevail. The board of directors of the Company (the “Board ”) reminds shareholders and potential investors of the Company that the information and financial data set out in this announcement are unaudited, have been reviewed by the audit committee but have not been reviewed by the independent auditors of the Company. The unaudited financial data in the 2025 Third Quarterly Report set out in this announcement is prepared in accordance with the accounting principles of the People ’s Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only. Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company. By order of the Board RemeGen Co., Ltd.* Mr. Wang Weidong Chairman and executive director Yantai, PRC October 30, 2025 As at the date of this announcement, the Board comprises Mr. Wang Weidong, Dr. Fang Jianmin, Mr. Lin Jian and Mr. Wen Qingkai as the executive directors, Dr. Wang Liqiang and Dr. Su Xiaodi as the non-executive directors, and Mr. Hao Xianjing, Mr. Chen Yunjin and Mr. Huang Guobin as the independent non-executive directors. * For identification purpose only
Page 2
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 11 / 1144 Stock Code: 688331 Ticker Symbol: RemeGen RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT The board of directors and all directors of the Company undertake that there are no false representations or misleading statements contained in, or material omissions from, this announcement, and accept responsibilities for the truthfulness, accuracy and completeness of its contents in accordance with the applicable laws. IMPORTANT NOTICE: The board of directors, directors and senior management of the Company undertake that the content of the quarterly report is true, accurate, complete and without any false records, misleading statements or material omissions and are severally and jointly liable therefor. The Company’s legal representative, person in charge of accounting function and person in charge of the accounting department (chief accounting officer) warrant the truthfulness, accuracy and completeness of the financial statements contained in the quarterly report. Whether the third quarterly financial statements have been audited □Yes √No I. KEY FINANCIAL INFORMATION (i) Key accounting data and financial indicators Unit: RMB Currency: Renminbi
Page 3
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 22 / 1144 Item The Reporting Period Increase/decrease compared with the same period of the previous year (%) From the beginning of the year to the end of the Reporting Period Increase/decrease compared with the same period of the previous year (%) Operating revenue 621,879,591.47 33.13 1,719,833,029.78 42.27 Total profit -101,131,912.31 N/A -550,700,575.38 N/A Net profit attributable to shareholders of the listed company -101,131,912.31 N/A -550,700,575.38 N/A Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses -99,726,700.01 N/A -545,244,239.68 N/A Net cash flows from operating activities N/A N/A 217,057,433.94 N/A Basic earnings per share (RMB/share) -0.18 N/A -1.01 N/A Diluted earnings per share (RMB/share) -0.18 N/A -1.01 N/A Weighted average return on equity (%) -3.04 An increase of 8.26 percentage points -26.70 An increase of 10.22 percentage points Total R&D spending 243,367,673.06 -29.90 890,583,907.36 -22.79 R&D spending as a percentage of operating revenue (%) 39.13 A decrease of 43.63 percentage points 51.78 A decrease of 35.19 percentage points As at the end of the Reporting Period As at the end of the previous year Increase/decrease compared with the end of the previous year (%) Total assets 5,977,129,884.12 5,498,518,168.82 8.70 Owners' equity attributable to shareholders of the listed company 2,320,083,063.64 1,986,200,620.94 16.81 Note: “The Reporting Period" means the three-month period from the beginning of the quarter to the end of the quarter, the same hereinafter. (ii) Non-recurring items and amounts √Applicable □ Not Applicable
Page 4
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 33 / 1144 Unit: RMB Currency: Renminbi Non-recurring items Current amount Amount from the beginning of the year to the end of the Reporting Period Description Gains or losses on disposal of non- current assets, including the write-off of the asset impairment provisions -57,730.47 152,937.44 Net gains or losses on disposal of non- current assets Government grants recognised as current gains and losses, except those that are closely related to the Company's ordinary course of business operations, comply with national policies, granted based on determined standards, and have a lasting impact on the Company's profits and losses 2,346,324.54 5,869,377.03 Government grants recognised as other income Gains and losses from changes in fair value arising from financial assets and financial liabilities held by non- financial enterprises and profits and losses from disposal of financial assets and financial liabilities other than effective hedging business related to the Company’s ordinary course of business operations 1,238,226.39 1,900,018.06 Mainly due to gains from structured deposits Other non-operating income and expenses other than the above items -4,932,032.76 -13,378,668.23 Donation expenses in majority Other gains and losses items classified to non-recurring gains and losses - - Less: Impact on income tax - - Impact on non-controlling interests (after tax) - - Total -1,405,212.30 -5,456,335.70 Explanations are required for defining items that are not set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recurring Gains and Losses as non-recurring items with significant amounts and for defining the non-recurring items that are set out in the Explanatory Announcement No. 1 on Information Disclosure for Companies Offering Their Securities to the Public — Non-recu rring Gains and Losses as recurring items. √Applicable □ Not Applicable
Page 5
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 44 / 1144 Unit: RMB Currency: Renminbi Item Amount involved Reason Additional value-added tax deductions 5,837,121.14 Tax incentives for business activities Government grants related to long-term assets 7,439,117.42 Lasting impact on the Company's gains and losses (iii) Changes in key accounting data and financial indicators and reasons for changes √Applicable □ Not Applicable Item Percentage change (%) Primary reason Operating revenue_The Reporting Period 33.13 This was largely due to an increase in sales revenue as a result of the rise in sales volumes of telitacicept and disitamab vedotin for injection. Operating revenue_From the beginning of the year to the end of the Reporting Period 42.27 Total profit_The Reporting Period N/A This was largely due to a significant increase in product sales revenue, R&D pipeline optimization of the Company, a decrease in various R&D expenditures, and the Company’s execution of a license agreement with Vor Biopharma Inc. for the paid-licensing of its proprietary telitacicept, granting Vor Biopharma Inc. the exclusive right to develop and commercialize telitacicept worldwide (excluding Greater China). This resulted in a reduction in overseas clinical trial expenses for telitacicept, consequently leading to a substantial decrease in losses for the year. Total profit_From the beginning of the year to the end of the Reporting Period N/A Net profit attributable to shareholders of the listed company_The Reporting Period N/A Net profit attributable to shareholders of the listed company_From the beginning of the year to the end of the Reporting Period N/A Net profit attributable to shareholders of the listed company after deducting non- recurring gains and losses_The Reporting Period N/A Net profit attributable to shareholders of the listed company after deducting non- recurring gains and losses_From the beginning of the year to the end of the Reporting Period N/A Net cash flows from operating activities_From the beginning of the year to the end of the Reporting Period N/A This was largely due to new large- scale cash inflows from technology licensing during the year and an increase in cash received from the sale of goods and provision of services due to increased product sales, resulting in an increase in net cash flows from operating activities.
Page 6
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 55 / 1144 Basic earnings per share (RMB/share)_The Reporting Period N/A This was largely due to the reduction in net loss caused by the aforementioned reasons. Basic earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period N/A Diluted earnings per share (RMB/share)_The Reporting Period N/A Diluted earnings per share (RMB/share)_From the beginning of the year to the end of the Reporting Period N/A Total R&D spending_The Reporting Period -29.90 The Company optimized its R&D pipeline and various R&D expenditures decreased. Furthermore, the Company executed a license agreement with Vor Biopharma Inc. for the paid- licensing of its proprietary telitacicept, granting Vor Biopharma Inc. the exclusive right to develop and commercialize telitacicept worldwide (excluding Greater China). This resulted in a reduction in overseas clinical trial expenses for telitacicept. Total R&D spending_From the beginning of the year to the end of the Reporting Period -22.79 R&D spending as a percentage of operating revenue (%)_The Reporting Period A decrease of 43.63 percentage points The decrease in the ratio of R&D spending to operating revenue was due to a significant increase in operating revenue on one hand and a reduction in R&D spending caused by the aforementioned reasons on the other hand. R&D spending as a percentage of operating revenue (%)_From the beginning of the year to the end of the Reporting Period A decrease of 35.19 percentage points
Page 7
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 66 / 1144 II. SHAREHOLDER INFORMATION (i) Total number of ordinary shareholders, number of preferred shareholders with restored voting rights, and shareholding of the top ten shareholders Unit: share Total number of ordinary shareholders as at the end of the Reporting Period 15,267 Total number of preferred shareholders with restored voting rights as at the end of the Reporting Period (if any) - Shareholding of the top ten shareholders (excluding shares re-lent) Name of shareholder Nature of shareholder Number of shares held Shareholding ratio (%) Number of restricted shares held Number of restricted shares including shares re- lent Shares pledged, marked or frozen Share status Quantity HKSCC NOMINEES LIMITED Unknown 208,569,228 37.01 0 0 Unknown - Yantai Rongda Venture Capital Center (Limited Partnership) Domestic non-state- owned legal person 102,381,891 18.17 102,381,891 102,381,891 Nil 0 FANG JIANMIN Overseas legal person 26,218,320 4.65 26,218,320 26,218,320 Nil 0 Yantai Rongqian Enterprise Management Center (Limited Partnership) Domestic non-state- owned legal person 18,507,388 3.28 18,507,388 18,507,388 Nil 0 Yantai Rongyi Enterprise Management Center (Limited Partnership) Domestic non-state- owned legal person 16,630,337 2.95 16,630,337 16,630,337 Nil 0
Page 8
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 77 / 1144 I-Nova Limited Overseas legal person 13,600,000 2.41 13,600,000 13,600,000 Nil 0 Yantai Rongshi Enterprise Management Center (Limited Partnership) Domestic non-state- owned legal person 9,190,203 1.63 9,190,203 9,190,203 Nil 0 Hong Kong Securities Clearing Company Limited Overseas legal person 8,841,804 1.57 0 0 Nil 0 Bank of Communications Co., Ltd. – Wanjia Sector Selection Mixed Securities Investment Fund (LOF) Others 7,000,000 1.24 0 0 Nil 0 RongChang Holding Group LTD. Overseas legal person 4,111,338 0.73 4,111,338 4,111,338 Nil 0 Shareholding of the top ten holders of unrestricted shares (excluding shares re-lent) Name of shareholder Number of unrestricted outstanding shares held Share type and quantity Share type Quantity HKSCC NOMINEES LIMITED 208,569,228 Overseas listed foreign shares 208,569,228 Hong Kong Securities Clearing Company Limited 8,841,804 RMB- denominated ordinary shares 8,841,804 Bank of Communications Co., Ltd. – Wanjia Sector Selection Mixed Securities Investment Fund (LOF) 7,000,000 RMB- denominated ordinary shares 7,000,000
Page 9
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 88 / 1144 China Construction Bank Corporation – ICBC Credit Suisse Front Medical Securities Investment Fund (中國建設銀行股份有限公 司 – 工銀瑞信前沿醫療股 票型證券投資基金) 4,000,000 RMB- denominated ordinary shares 4,000,000 Bank of China Limited – Guangfa Healthcare Securities Investment Fund (中國銀行 股份有限公司 – 廣發醫療 保健股票型證券投資基金) 3,987,466 RMB- denominated ordinary shares 3,987,466 China Construction Bank Corporation – Huitianfu Innovative Medicine Theme Hybrid Securities Investment Fund (中國建設銀行股份有 限公司– 匯添富創新醫藥主 題混合型證券投資基金) 2,620,698 RMB- denominated ordinary shares 2,620,698 Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行 股份有限公司 — 招商國證 生物醫藥指數分級證券投資 基金) 2,399,379 RMB- denominated ordinary shares 2,399,379 PAG Growth Prosperity Holding I（HK）Limited 2,235,782 RMB- denominated ordinary shares 2,235,782 China Minsheng Banking Corp., Ltd. - BOC Innovative Healthcare Hybrid Securities Investment Fund (中國民生 銀行股份有限公司－中銀創 新醫療混合型證券投資基 金) 2,156,285 RMB- denominated ordinary shares 2,156,285 Beijing Lapam Healthcare Investment Centre (Limited Partnership) (北京龍磐健康 醫療投資中心(有限合夥) 2,092,002 RMB- denominated ordinary shares 2,092,002
Page 10
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 99 / 1144 Description of the connected relationship or concerted actions among the above shareholders Yantai Rongda Venture Capital Center (L imited Partnership), FANG JIANMIN, I-Nova Limited, and RongChang Holding Group LTD. had a relationship of acting in concert Description of participation of top ten shareholders and top ten holders of unrestricted shares in margin trading and re-lending business (if any) Nil Note 1: The shares held by HKSCC NOMINEES LIMITED (香港中央結算(代理人)有限公司) are shares that it holds on behalf of several clients, and part of the H shares held by I-Nova Limited and RongChang Holding Group LTD. are registered under HKSCC NOMINEES LIMITED. Note 2: As of the end of the Reporting Period, there were a total number of 15,248 Class A ordinary shareholders and 19 Class H ordinary shareholders, totalling 15,267 ordinary shareholders. Participation of Shareholders with more than 5% shareholding, top ten shareholders and top ten holders of unrestricted outstanding shares in re-lending business □Applicable √ Not Applicable Changes in top ten shareholders and top ten holders of unrestricted outstanding shares from the previous period attributable to re-lending/returning □Applicable √ Not Applicable III. OTHER REMINDERS Other important information about the operation of the Company during the Reporting Period that investors should be reminded of □Applicable √ Not Applicable IV. QUARTERLY FINANCIAL STATEMENTS (i) Types of audit opinions □Applicable √ Not Applicable (ii) Financial statements Consolidated Balance Sheet September 30, 2025 Prepared by: RemeGen Co., Ltd.* Unit: RMB Currency: Renminbi Audit type: Unaudited Item September 30, 2025 December 31, 2024 Current assets: Cash and bank balances 1,070,277,163.56 762,492,395.54 Held-for-trading financial assets 109,343,391.25 - Bills receivable 201,780,450.58 204,299,928.35 Accounts receivable 361,989,041.99 383,388,743.02 Receivables financing 66,649,661.83 11,097,822.85
Page 11
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 1100 / 1144 Prepayments 199,387,966.97 241,373,752.00 Other receivables 50,495,704.79 24,283,132.94 Inventories 657,583,963.29 659,368,730.71 Other current assets 1,635,532.68 3,491,867.90 Total current assets 2,719,142,876.94 2,289,796,373.31 Non-current assets: Long-term equity investments 11,259,100.76 8,850,723.90 Investments in other equity instruments 119,152,359.03 59,313,437.97 Other non-current financial assets 11,537,475.88 4,037,475.88 Fixed assets 2,323,127,608.78 2,457,180,322.07 Construction in progress 535,489,814.61 283,231,455.78 Right-of-use assets 48,418,068.25 93,753,714.63 Intangible assets 154,667,578.99 143,131,261.71 Long-term deferred expenses 1,599,492.74 4,324,896.83 Other non-current assets 52,735,508.14 154,898,506.74 Total non-current assets 3,257,987,007.18 3,208,721,795.51 Total assets 5,977,129,884.12 5,498,518,168.82 Current liabilities: Short-term borrowings 1,071,410,580.80 1,083,853,548.13 Accounts payable 194,761,229.05 162,250,106.68 Contract liabilities 571,834,427.34 3,143,688.86 Payroll payable 213,004,511.36 209,986,022.76 Taxes payable 48,468,857.92 37,058,544.84 Other payables 320,588,843.38 314,995,392.79 Non-current liabilities due within one year 390,029,409.55 348,684,938.40 Other current liabilities 22,700,635.28 18,324,410.71 Total current liabilities 2,832,798,494.68 2,178,296,653.17 Non-current liabilities: Long-term borrowings 696,200,059.51 1,195,878,046.86 Lease liabilities 25,274,131.90 42,093,510.05 Deferred income 92,935,766.23 96,049,337.80 Deferred tax liabilities 9,838,368.16 - Total non-current liabilities 824,248,325.80 1,334,020,894.71 Total liabilities 3,657,046,820.48 3,512,317,547.88 Owners’ equity (or shareholders’ equity): Paid-in capital (or share capital) 563,608,243.00 544,332,083.00 Capital reserve 6,923,757,144.60 6,290,989,900.90 Less: Treasury shares 262,382,928.10 445,329,702.16 Other comprehensive income -32,327,629.91 -81,920,470.23 Retained earnings -4,872,571,765.95 -4,321,871,190.57
Page 12
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 1111 / 1144 Total equity attributable to owners (or shareholders) of the parent company 2,320,083,063.64 1,986,200,620.94 Total owners’ equity (or shareholders’ equity) 2,320,083,063.64 1,986,200,620.94 Total liabilities and owners’ equity (or shareholders’ equity) 5,977,129,884.12 5,498,518,168.82 The Company’s legal representative: Wang Weidong Person in charge of accounting function: Tong Shaojing Person in charge of the accounting department: Wei Jianliang Consolidated Statement of Income January-September 2025 Prepared by: RemeGen Co., Ltd.* Unit: RMB Currency: Renminbi Audit type: Unaudited Item First three quarters of 2025 (January-September) First three quarters of 2024 (January-September) I. Total operating revenue 1,719,833,029.78 1,208,874,280.23 Including: Operating revenue 1,719,833,029.78 1,208,874,280.23 II. Total operating costs 2,268,418,316.44 2,316,244,667.13 Including: Operating costs 270,593,449.58 244,744,865.10 Taxes and surcharges 12,367,642.39 11,272,616.41 Selling expenses 822,658,892.95 622,700,750.52 Administrative expenses 215,621,316.70 234,621,471.72 R&D expenses 890,583,907.36 1,153,407,440.34 Finance costs 56,593,107.46 49,497,523.04 Including: Interest expenses 57,040,326.33 55,598,761.08 Interest income 3,570,684.25 8,544,332.69 Add: Other income 19,145,615.59 65,240,530.15 Gain from investment (loss denoted by “-”) -4,686,557.89 1,241,939.00 Including: Gain from investments in associates and joint ventures 408,376.86 -104,902.37 Gain on derecognition of financial assets measured at amortised cost 1,606,295.09 1,360,416.66 Gain from changes in fair value (loss denoted by “-”) 293,722.97 718,287.12 Credit impairment loss (loss denoted by “-”) -3,632,557.18 -5,774,013.88 Asset impairment loss (loss denoted by “-”) -9,781.42 -10,006,510.93 Gain on disposal of assets (loss denoted by “-”) 205,690.01 88,364.48 III. Operating profit (loss denoted by “-”) -537,269,154.58 -1,055,861,790.96 Add: Non-operating income 797,697.78 1,565,965.93
Page 13
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 1122 / 1144 Less: Non-operating expenses 14,229,118.58 17,130,813.87 IV. Total profit (total loss denoted by “-”) -550,700,575.38 -1,071,426,638.90 Less: Income tax expenses - - V. Net profit (net loss denoted by “-”) -550,700,575.38 -1,071,426,638.90 (i) By continuity of operations 1. Net profit from continuing operations (net loss denoted by “-”) -550,700,575.38 -1,071,426,638.90 (ii) By attribution of ownership 1. Net profit attributable to shareholders of the parent company (net loss denoted by “-”) -550,700,575.38 -1,071,426,638.90 VI. Other comprehensive income, net of tax 49,592,840.32 -42,366,321.69 (i) Other comprehensive income attributable to owners of the parent company, net of tax 49,592,840.32 -42,366,321.69 1. Other comprehensive income not to be reclassified to profit or loss 50,000,552.90 -38,099,566.59 (1) Changes in fair value of other equity instruments investments 50,000,552.90 -38,099,566.59 2. Other comprehensive income to be reclassified to profit or loss -407,712.58 -4,266,755.10 (1) Translation differences of the financial statements in foreign currency -407,712.58 -4,266,755.10 VII. Total comprehensive income -501,107,735.06 -1,113,792,960.59 (i) Total comprehensive income attributable to owners of the parent company -501,107,735.06 -1,113,792,960.59 VIII. Earnings per share: (i) Basic earnings per share (RMB/share) -1.01 -1.99 (ii) Diluted earnings per share (RMB/share) -1.01 -1.99 In case of a business combination under common control during the period, the net profit of the combined party which has been realised prior to the combination was RMB0, and the net profit of the combined party which has been realised in the previous period was RMB0. The Company’s legal representative: Wang Weidong Person in charge of accounting function: Tong Shaojing Person in charge of the accounting department: Wei Jianliang
Page 14
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 1133 / 1144 Consolidated Statement of Cash Flows January-September 2025 Prepared by: RemeGen Co., Ltd.* Unit: RMB Currency: Renminbi Audit type: Unaudited Item First three quarters of 2025 (January-September) First three quarters of 2024 (January-September) I. Cash flows from operating activities: Cash receipts from sales of goods and provision of services 2,229,797,482.86 1,097,729,076.75 Tax refund received 3,199.68 14,112,207.51 Cash received from other operating activities 26,135,188.33 110,331,330.11 Sub-total of cash inflows from operating activities 2,255,935,870.87 1,222,172,614.37 Cash paid for goods and services 104,074,192.63 103,969,884.33 Cash paid to and on behalf of employees 776,054,088.56 837,884,001.41 Cash paid for taxes and levies 106,451,519.86 37,431,526.62 Cash paid for other operating activities 1,052,298,635.88 1,077,990,268.89 Sub-total of cash outflows from operating activities 2,038,878,436.93 2,057,275,681.25 Net cash flows from operating activities 217,057,433.94 -835,103,066.88 II. Cash flows from investment activities: Cash received from the disposal of investments 1,050,000,000.00 520,078,626.05 Cash received from investment income 1,606,295.09 1,360,416.66 Net cash received from the disposal of fixed assets, intangible assets and other long-term assets 1,610,219.63 5,461,797.61 Cash received from other investment activities 9,578,400.00 13,994,347.44 Sub-total of cash inflows from investment activities 1,062,794,914.72 540,895,187.76 Cash paid for acquisition of fixed assets, intangible assets and other long-term assets 175,212,674.86 179,951,645.19 Cash paid for investments 1,167,127,956.20 786,750,000.00 Sub-total of cash outflows from investment activities 1,342,340,631.06 966,701,645.19 Net cash flows from investing activities -279,545,716.34 -425,806,457.43
Page 15
RemeGen Co., Ltd.* 2025 THIRD QUARTERLY REPORT 1144 / 1144 III. Cash flows from financing activities: Cash received from capital contributions 783,623,475.65 1,032,897.91 Cash received from borrowings 1,333,647,815.42 1,315,592,447.57 Sub-total of cash inflows from financing activities 2,117,271,291.07 1,316,625,345.48 Cash paid for repayment of debts 1,630,099,036.42 1,569,400.00 Cash paid for distribution of dividends or profits or settlement of interest 66,397,042.91 53,218,519.45 Cash paid for other financing activities 49,806,464.41 59,778,979.19 Sub-total of cash outflows from financing activities 1,746,302,543.74 114,566,898.64 Net cash flows from financing activities 370,968,747.33 1,202,058,446.84 IV. Effects of changes in exchange rate on cash and cash equivalents -620,373.83 -5,694,629.93 V. Net increase in cash and cash equivalents 307,860,091.10 -64,545,707.40 Add: Balance of cash and cash equivalents at the beginning of the period 759,530,043.42 726,551,931.36 VI. Balance of cash and cash equivalents at the end of the period 1,067,390,134.52 662,006,223.96 The Company’s legal representative: Wang Weidong Person in charge of accounting function: Tong Shaojing Person in charge of the accounting department: Wei Jianliang Adjustment of the financial statements for the beginning of 2025 when the Company implements the new accounting standards or interpretations for the first time □Applicable √ Not Applicable This is hereby notified. Board of directors of RemeGen Co., Ltd.∗ October 30, 2025